Last reviewed · How we verify

QVM149 — Competitive Intelligence Brief

QVM149 (QVM149) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: GLP-1 receptor agonist and glucagon receptor antagonist. Area: Diabetes.

phase 3 GLP-1 receptor agonist and glucagon receptor antagonist GLP-1R, glucagon receptor Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

QVM149 (QVM149) — Dr. Grace Parraga. QVM149 is a dual combination of a glucagon receptor antagonist and a glucagon-like peptide-1 (GLP-1) receptor agonist.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
QVM149 TARGET QVM149 Dr. Grace Parraga phase 3 GLP-1 receptor agonist and glucagon receptor antagonist GLP-1R, glucagon receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (GLP-1 receptor agonist and glucagon receptor antagonist class)

  1. Dr. Grace Parraga · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). QVM149 — Competitive Intelligence Brief. https://druglandscape.com/ci/qvm149. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: